Suchergebnisse - "Rossetti, Sabrina"

PubPharm (87)

1

Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors

enthalten in: Cancers | 2023

von Di Costanzo, F. | Napolitano, F. | Salomone, F. | +14

2

Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor : A tertiary care experience

enthalten in: Asian journal of urology | 2023

von Franzese, D. | Tufano, A. | Izzo, A. | +11

3

Feasibility of cabazitaxel in octogenarian prostate cancer patients

enthalten in: Current urology | 2023

von Tralongo, P. | Bordonaro, S. | Di Lorenzo, G. | +11

4

The role of immunotherapy treatment in non-clear cell renal cell carcinoma : An analysis of the literature

enthalten in: Critical reviews in oncology/hematology | 2023

von Ventriglia, J. | Passarelli, A. | Pisano, C. | +9

5

First-line treatment of metastatic castration-resistant prostate cancer : the real-world Italian cohort of the Prostate Cancer Registry

enthalten in: Tumori | 2023

von Galli, L. | Chiuri, V. | Di Lorenzo, G. | +20

6

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Journal of translational medicine | 2023

von Nuzzo, P. | Pederzoli, F. | Saieva, C. | +16

7

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Journal of translational medicine | 2023

von Nuzzo, P. | Pederzoli, F. | Saieva, C. | +15

8

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Journal of translational medicine | 2023

von Nuzzo, P. | Pederzoli, F. | Saieva, C. | +15

9

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer : clinical outcomes and toxicities of CyPro Trial

enthalten in: Frontiers in oncology | 2023

von Borzillo, V. | Scipilliti, E. | Pezzulla, D. | +16

10

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Therapeutic advances in medical oncology | 2023

von Nuzzo, P. | Ravera, F. | Saieva, C. | +16

ErratumIn: Ther Adv Med Oncol. 2023 Jun 16;15:17588359231182232. - PMID 37342256

1
2
3
4
5
6
7
8
9
Nächster »
[9]